UBS O'Connor’s Immunocore IMCR Stock Holding History

UBS O'Connor’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-30,000	Closed	-$94.5K	–	551
2024 Q2	$94.5K	Buy	+30,000	New	+$1.53M	﹤0.01%	434

Other funds holding IMCR

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

UBS O'Connor's IMCR Position: Q3 2025 in Review

UBS O'Connor sold out of Immunocore (IMCR) in Q3 2025, closing a stake of 53,343 shares — an estimated $1.67M sold.

UBS O'Connor first reported a position in IMCR in Q1 2022 and held it in 14 quarters. The position peaked at $2.42M in Q2 2023. 132 funds tracked by Wall St. Rank hold IMCR as of Q3 2025.

UBS O'Connor reported no remaining Immunocore position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 53,343 Immunocore shares in Q3 2025, an estimated $1.67M.
UBS O'Connor first reported a position in Immunocore in Q1 2022 and held it in 14 quarters.
UBS O'Connor's Immunocore position peaked at $2.42M in Q2 2023.
132 funds tracked by Wall St. Rank held Immunocore as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.